Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At.
The introduction of the short-lived α-emitter (211)At to intraperitoneal radioimmunotherapy has raised the issue of the tolerance dose of the peritoneum. The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues. To address this issue, mice were injected with (211)At-trastuzumab to irradiate the peritoneum to absorbed doses ranging between 0 and 50 Gy and followed for up to 34 weeks. The peritoneum-to-plasma clearance of a small tracer, (51)Cr-ethylenediamine tetraacetic acid, was measured for evaluation of the small solute transport capacity of the peritoneal membrane. The macroscopic status of the peritoneum and the mesenteric windows was documented when the mice were sacrificed. Biopsies of the peritoneum were taken for morphology and immunohistochemical staining against plasminogen activator inhibitor-1 and calprotectin. Peritoneum-to-plasma clearance measurements indicated a dose-dependent decrease in peritoneal transport capacity in irradiated mice. However, macroscopic and microscopic evaluations of the peritoneal membrane showed no difference between irradiated mice versus controls. The results imply that the peritoneal membrane tolerates absorbed doses as high as 30-50 Gy from α-particle irradiation with limited response.
Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. elin.cederkrantz@radfys.gu.se
Elin
E
Cederkrantz
Eva
E
Angenete
Tom
T
Bäck
Peter
P
Falk
Börje
B
Haraldsson
Marie-Louise
ML
Ivarsson
Holger
H
Jensen
Sture
S
Lindegren
Ragnar
R
Hultborn
Lars
L
Jacobsson
D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D001246:Astatine / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010537:Peritoneum / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects*; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000922:Immunotoxins; D019275:Radiopharmaceuticals; D000068878:Trastuzumab; D001246:Astatine